31st Annual Meeting

November 11-13, 2016
Gaylord National Hotel & Convention Center

Organizers

Chair: Lisa H. Butterfield, PhD – University of Pittsburgh
James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Holbrook E. Kohrt, MD, PhD* – Stanford Cancer Institute

Program Purpose

The SITC 31^st Annual Meeting provides a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consists of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting includes updates on major national and international initiatives coming from academia, government and industry, as well as important Society projects.

Following SITC’s tradition of collaborating to advance the field, the 31^st Annual Meeting features numerous sessions collaboratively-developed with reputable organizations whose missions complement and align with that of SITC’s. An in-depth Value of Cancer Immunotherapy Summit, organized in collaboration with the American Society of Clinical Oncology, is prominently featured to discuss a crucial topic that impacts all cancer immunotherapy constituents, from researchers and clinicians to payers and cancer patients.

Intended Audience

The audience includes U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This includes, but is not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.

Educational Objectives

Upon completion of this meeting, participants are now able to:

Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research

Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy

Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic interventions

For information on continuing medical education credits available through SITC's 31^st Annual Meeting, please visit our Continuing Education Credit page.

The SITC Annual Meeting is supported in part by grants from 7 Hills Pharma, LLC; AbbVie; Aduro Biotech, Inc.; Affymetrix, a part of Thermo Fisher Scientific; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Charles River; Eli Lilly and Company; Fluidigm Corporation; Genentech; HalioDx; Idera Pharmaceuticals; Incyte Corporation; Janssen Research & Development, LLC; Juno Therapeutics; Mallinckrodt Pharmaceuticals; Merck & Co., Inc.; NanoString Technologies; Nektar Therapeutics; Novartis Oncology; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Prometheus Laboratories Inc.; Provectus Biopharmaceuticals, Inc.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact SITC prior to the live event at +1 414-271-2456.

*Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016)
Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC. Dr. Kohrt was actively involved in the development of SITC’s 31^st Annual Meeting as an Organizer and session Co-Chair up until the time of passing. As such, the 31^st Annual Meeting will contain a fitting tribute to his memory and his many contributions to the field.